Final Results of a Phase 1b Study of BET Inhibitor PLX2853 in Patients with Relapsed or Refractory Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome

被引：3

作者：

Mims, Alice S. ^{[1
]}

Solh, Melhem ^{[2
]}

Saultz, Jennifer N. ^{[3
]}

Borate, Uma ^{[4
]}

Pemmaraju, Naveen ^{[5
]}

Borthakur, Gautam ^{[5
]}

Roboz, Gail J. ^{[6
]}

Powell, Ben ^{[7
]}

Matusow, Bernice ^{[7
]}

Halladay, Jason ^{[7
]}

Vali, Shireen ^{[7
]}

Hope, Chelsea L. ^{[7
]}

Kundu, Madan G. ^{[8
]}

Hsu, Ching ^{[8
]}

Watkins, Paul ^{[7
]}

Zhang, Chao ^{[7
]}

Walling, Jackie M. ^{[7
]}

Tsiatis, Athanasios C. ^{[7
]}

DeZern, Amy E. ^{[9
]}

机构：

[1] Ohio State Univ, Ctr Comprehens Canc, Clara Bloomfield Ctr Leukemia Outcomes Res, Columbus, OH 43210 USA

[2] Northside Hosp Canc Inst, Atlanta, GA USA

[3] Oregon Hlth & Sci Univ, Knight Canc Inst, Portland, OR USA

[4] Ohio State Univ, James Canc Ctr, Columbus, OH USA

[5] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA

[6] Cornell Univ, Weill Med Coll, Div Hematol Oncol, Dept Med, York, NY USA

[7] Plexxikon Inc, Berkeley, CA USA

[8] Daiichi Sankyo, Basking Ridge, NJ USA

[9] Johns Hopkins Univ, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD 21218 USA

来源：

BLOOD | 2021年 / 138卷

关键词：

D O I：

10.1182/blood-2021-152040

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

3420

引用

页数：6

共 50 条

[1] Phase 1b Study of BET Inhibitor PLX2853 in Patients with Relapsed or Refractory Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome
Mims, Alice S.
Solh, Melhem
Borate, Uma
Pemmaraju, Naveen
Borthakur, Gautam
Roboz, Gail J.
Powell, Ben
Severson, Paul
Matusow, Bernice
Halladay, Jason
Hsu, Ching
Watkins, Paul
Zhang, Chao
Walling, Jackie M.
Tsiatis, Athanasios C.
DeZern, Amy E.
BLOOD, 2020, 136
[2] Dose Escalation Study of BET Inhibitor PLX2853 in Patients with Relapsed or Refractory Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome
Pemmaraju, Naveen
Borate, Uma
Solh, Melhem
Borthakur, Gautam M.
DeZern, Amy E.
Zhang, Chao
Powell, Ben
Severson, Paul
Inokuchi, Kerry
Matusow, Bernice
Halladay, Jason
Hsu, Ching
Watkins, Paul
Walling, Jackie M.
Tsiatis, Athanasios C.
Mims, Alice S.
BLOOD, 2019, 134
[3] Phase 1 Results of Novel Combination Therapy: BET Inhibitor PLX51107 with Azacitidine in Patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)
Pemmaraju, Naveen
Bhalla, Kapil N.
Daver, Naval
Wilson, Nathaniel R.
Fiskus, Warren C.
Ravandi, Farhad
Garcia-Manero, Guillermo
Kadia, Tapan M.
DiNardo, Courtney D.
Jabbour, Elias J.
Burger, Jan A.
Short, Nicholas J.
Alvarado, Yesid
Jain, Nitin
Masarova, Lucia
Verstovsek, Srdan
Issa, Ghayas C.
Qiao, Wei
Khoury, Joseph D.
Pierce, Sherry A.
Miller, Darla
Konopleva, Marina
Kantarjian, Hagop
Borthakur, Gautam
BLOOD, 2021, 138
[4] Phase 1b/2a study of PLX2853, a small molecule BET inhibitor, in subjects with advanced solid tumors and lymphoma.
Gordon, Michael S.
Carvajal, Richard D.
Spira, Alexander I.
Huang, Marilyn
Watkins, Paul
Powell, Ben
Inokuchi, Kerry
Sterba, Michael
Matusow, Bernice
Hope, Chelsea
Halladay, Jason
Zhang, Chao
Walling, Jacqueline M.
Tsiatis, Athanasios C.
Patnaik, Amita
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[5] A phase 1b study of venetoclax and alvocidib in patients with relapsed/refractory acute myeloid leukemia
Jonas, Brian A.
Hou, Jing-Zhou
Roboz, Gail J.
Alvares, Caroline L.
Jeyakumar, Deepa
Edwards, John R.
Erba, Harry P.
Kelly, Richard J.
Roellig, Christoph
Fiedler, Walter
Brackman, Deanna
Siddani, Satya R.
Chyla, Brenda
Hilger-Rolfe, Jacqueline
Watts, Justin M.
HEMATOLOGICAL ONCOLOGY, 2023, 41 (04) : 743 - 752
[6] Final results of a phase 2, open-label study of indisulam, idarubicin, and cytarabine in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome
Assi, Rita
Kantarjian, Hagop M.
Kadia, Tapan M.
Pemmaraju, Naveen
Jabbour, Elias
Jain, Nitin
Daver, Naval
Estrov, Zeev
Uehara, Taisuke
Owa, Takashi
Cortes, Jorge E.
Borthakur, Gautam
CANCER, 2018, 124 (13) : 2758 - 2765
[7] Update of a phase I study of sorafenib in patients with refractory/relapsed acute myeloid leukemia or high-risk myelodysplastic syndrome
Delmonte, John, Jr.
Kantarjian, Hagop M.
Andreef, Michael
Faderl, Stefan
Wright, John J.
Zhang, Weiguo
Konopleva, Marina
Verstovsek, Srdan
Borthakur, Gautam
Ravandi, Farhad
Cortes, Jorge
BLOOD, 2007, 110 (11) : 272A - 273A
[8] Phase 1 Study of BXCL701, a Dipeptidyl Peptidase Inhibitor, in Relapsed/Refractory Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome
Winer, Eric S.
Garcia, Jacqueline S.
Stone, Richard M.
Wadleigh, Martha
Luskin, Marlise R.
Stahl, Maximilian
Chen, Evan C.
Leonard, Rebecca
Noyes, Alexis
Galinsky, Ilene
Deshpande, Rashmi
Borderies, Pascal
O'Neill, Vincent
DeAngelo, Daniel J.
BLOOD, 2023, 142
[9] Venetoclax in Combination with Gilteritinib in Patients with Relapsed/Refractory Acute Myeloid Leukemia: A Phase 1b Study
Perl, Alexander E.
Daver, Naval G.
Pratz, Keith W.
Maly, Joseph
Hong, Wan-Jen
Bahceci, Erkut
Tong, Bo
Tian, Tian
Dilley, Kimberley
BLOOD, 2019, 134
[10] Phase 1 study of CWP232291 in patients with relapsed or refractory acute myeloid leukemia and myelodysplastic syndrome
Lee, Je-Hwan
Faderl, Stefan
Pagel, John M.
Jung, Chul Won
Yoon, Sung-Soo
Pardanani, Animesh D.
Becker, Pamela S.
Lee, Howard
Choi, Jeongeun
Lee, Kyoungjune
Kim, Minkyoung
Cortes, Jorge E.
BLOOD ADVANCES, 2020, 4 (09) : 2032 - 2043

← 1 2 3 4 5 →